The global clinical trials activity saw a decrease of 4.4% in Q2 2022, when compared with the rolling average of the last four quarters (Q2 2021 to Q1 2022), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 52.9% share in Q2 2022, marking an increase of 3.0% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 47.1% share of all the clinical trials globally in Q2 2022, marking a decrease of 3.0% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q2 2022
Oncology was the leading therapy area for industry sponsored clinical trials in Q2 2022, accounting for a 31.7% share of all trials.
This was followed by the following therapy areas: Central Nervous System with a 14.0% share, Infectious Disease with a 13.8% share, Cardiovascular with a 7.7% share, and Metabolic Disorders with a 7.4% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.7% share, followed by Infectious Disease with a 16.4% share, Central Nervous System with a 14.1% share, Metabolic Disorders with an 8.3% share, and Cardiovascular with a 7.9% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q2 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q2 2022 | Activity |
| Oncology | 27.7% | 31.7% |  |
| Central Nervous System | 14.1% | 14.0% |  |
| Infectious Disease | 16.4% | 13.8% | |
| Cardiovascular | 7.9% | 7.7% | |
| Metabolic Disorders | 8.3% | 7.4% | |
| Gastrointestinal | 6.7% | 5.7% | |
| Respiratory | 5.7% | 5.2% | |
| Dermatology | 4.9% | 4.7% | |
| Immunology | 5.6% | 4.6% | |
| Musculoskeletal Disorders | 4.0% | 3.5% | |
| Hematological Disorders | 2.7% | 3.2% | |
| Genito Urinary System And Sex Hormones | 2.8% | 2.7% | |
| Ophthalmology | 2.8% | 2.6% | |
| Genetic Disorders | 1.6% | 2.5% | |
| Ear Nose Throat Disorders | 1.6% | 1.3% | |
| Women’s Health | 1.9% | 1.3% | |
| Male Health | 1.0% | 0.7% | |
| Hormonal Disorders | 0.8% | 0.6% | |
| Mouth and Dental Disorders | 0.5% | 0.4% | |
| Nutritional Disorders | 0.3% | 0.3% | |
| Non Malignant Disorders | 0.3% | 0.2% | |
Oncology was the leading therapy area for non-industry sponsored clinical trials in Q2 2022, accounting for a 25.7% share of all trials.
This was followed by the following therapy areas: Central Nervous System with a 25.6% share, Infectious Disease with an 11.4% share, Cardiovascular with a 9.8% share, and Metabolic Disorders with a 5.9% share.
In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 24.4%, followed by Oncology with a 23.1% share, Infectious Disease with a 14.1% share, Cardiovascular with a 9.0% share, and Gastrointestinal with a 6.5% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q2 2022 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q2 2022 | Activity |
| Oncology | 23.1% | 25.7% | |
| Central Nervous System | 24.4% | 25.6% | |
| Infectious Disease | 14.1% | 11.4% | |
| Cardiovascular | 9.0% | 9.8% | |
| Metabolic Disorders | 5.5% | 5.9% | |
| Gastrointestinal | 6.5% | 5.6% | |
| Musculoskeletal Disorders | 5.0% | 5.5% | |
| Respiratory | 4.1% | 4.1% | |
| Women’s Health | 4.5% | 3.9% | |
| Immunology | 3.2% | 2.7% | |
| Genito Urinary System And Sex Hormones | 2.9% | 2.6% | |
| Dermatology | 2.8% | 2.5% | |
| Hematological Disorders | 3.0% | 2.4% | |
| Mouth and Dental Disorders | 2.4% | 2.2% | |
| Ophthalmology | 1.9% | 1.5% | |
| Ear Nose Throat Disorders | 1.1% | 1.3% | |
| Genetic Disorders | 0.6% | 1.0% | |
| Nutritional Disorders | 0.8% | 0.9% | |
| Hormonal Disorders | 0.9% | 0.5% | |
| Male Health | 0.6% | 0.5% | |
| Non Malignant Disorders | 0.3% | 0.4% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q2 2022
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q2 2022 with a 52.6% share, compared to 56.0% in the last four quarters.
North America stood at second place with a 32.0% share in Q2 2022, over 30.1% in the last four quarters, followed by Europe with a 28.2% share in Q2 2022, as against 27.4% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.3% share in industry sponsored clinical trials in Q2 2022 when compared with 84.8% of average recorded in the last four quarters. Multinational trials accounted for a 14.7% share in Q2 2022, as against the four-quarter average of 15.2%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q2 2022 with a 55.5% share, over 51.8% in the last four quarters.
North America held the second position with a 21.6% share in Q2 2022, over 15.8% in the last four quarters, followed by Europe with a 14.1% share in Q2 2022, as against 14.2% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 98.7% share for non-industry sponsored clinical trials in Q2 2022, compared to 99.0% in the last four quarters. Multinational trials accounted for a 1.3% share in Q2 2022, as against 1.0% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q2 2022
Phase II trials outnumbered all other studies with a 37.7% share for industry sponsored trials in Q2 2022, compared to 34.3% average in the last four quarters.
The share of Phase I trials stood at 35.8% in Q2 2022, as against the four-quarter average of 38.3%. Phase III trials held a 16.0% share in Q2 2022, remaining flat over the last four quarters average, followed by Phase IV trials with a 10.5% share in Q2 2022, as against the four-quarter average of 11.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 48.4% share for non-industry sponsored clinical trials in Q2 2022, compared to 42.7% in the last four quarters.
Phase IV trials stood at second place with a 21.1% share in Q2 2022, compared to 22.5% in the last four quarters. Phase I trials held a 17.8% share in Q2 2022, as against 16.0% in the last four quarters, followed by Phase III trials with a 12.8% share in Q2 2022 over 18.8% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
